

MAY 20 2011

**510K Summary**

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 CFR 807-92(c).

1. The submitter of this pre-market notification is:

Mary Kruitwagen  
Philips Medical Systems  
3000 Minuteman Road  
Andover, MA 01810  
United States

Tel: 978-659-4932

Fax: 978-685-5624

Email: [mary.kruitwagen@philips.com](mailto:mary.kruitwagen@philips.com)

This summary was prepared on March 10, 2011.

2. a) The name of the subject device is Philips SureSigns VSi Vital Signs Monitor.  
b) The trade name of the device is SureSigns VSi Vital Signs Monitor.  
c) The common usual name is multi-parameter patient monitor  
4) The Classification names are as follows:

Device Panel	Classification	ProCode	Description	VSi	M1196S
Cardiovascular	870.1110, II	DSK	Computer, Blood Pressure	yes	no
	870.1130, II	DXN	System, Measurement, Blood Pressure, Non-Invasive	yes	no
	870.2700, II	DQA	Oximeter	yes	yes
General Hospital and Personal Use	880.2910, II	FLL	Thermometer, Electronic, Clinical	yes	no

3. The modified devices are substantially equivalent to previously cleared Philips device, SureSigns VS2 cleared under K082280 and K090483, in a.
4. The modifications are as follows:
- Introduction of the VSi Vital Signs monitor (the predicate device is VS2)
5. The subject devices have a different intended use than the legally marketed predicate device SureSigns VS2. The indications for use is unchanged although the available measurements are listed. The SureSigns VSi Vital Signs monitor is indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients. The SureSigns VSi vital signs monitor is for measurement of multiple physiological parameters of adults, pediatrics and neonates in healthcare environments. Additionally, the monitor is intended for use in transport situations within a healthcare facility
6. The subject devices have the same fundamental technological characteristics as the legally marketed predicate device. The subject devices use the same algorithms for the measurements as the predicate device. The VSi is different from the predicate device in that is has no physiological alarms, performs no continuous monitoring, has an internal power

supply, and uses keys for navigation (no navigation wheel). The VSi stores less records than the predicate and does not have wireless communication.

Verification, validation, and testing activities establish the performance, functionality, and reliability characteristics of the subject device. Testing involved system level tests, performance tests, and safety testing from hazard analysis. Pass/Fail criteria were based on the specifications cleared for the subject device and test results showed substantial equivalence. The results demonstrate that the Philips SureSigns VSi Vital Signs monitor meets all reliability requirements and performance claims and supports a determination of substantial equivalence.



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room -WO66-G609  
Silver Spring, MD 20993-0002

Philips Medical Systems.  
c/o Ms. Mary Kruitwagen  
Regulatory Affairs Specialist  
Philips Medical Systems  
3000 Minuteman Road  
Andover, MA 01810

MAY 20 2011

Re: K110803  
Trade/Device Name: SureSigns VSi Vital Signs Monitor  
Regulation Number: 21 CFR 870.1130  
Regulation Name: Non-Invasive Blood Pressure Measurement System  
Regulatory Class: Class II (two)  
Product Codes: DXN, DQA, FLL  
Dated: March 22, 2011  
Received: March 23, 2011

Dear Ms. Kruitwagen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

  
Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**Indications for Use**

510 (k) Number (if known): K110803

**Device Name:** SureSigns VSi (reference numbers: 863275, 863276, 853277)

**Indications for Use:**

Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients.


Standard and optional parameters include:

- NBP
- SpO<sub>2</sub>
- Temperature

Prescription Use: YES AND/OR over-the-counter Use: NO  
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED  
Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1

  
**(Division Sign-Off)**  
**Division of Cardiovascular Devices**

510(k) Number K110803